Preview

Атеротромбоз

Расширенный поиск

ПРОБЛЕМА ВНУТРИЧЕРЕПНЫХ КРОВОИЗЛИЯНИЙ НА ФОНЕ ПРИЕМА «НОВЫХ» АНТИ КОАГУЛЯНТОВ

https://doi.org/10.21518/2307-1109-2014-2-58-69

Полный текст:

Аннотация

Высокая распространенность тромботических осложнений у пациентов с сердечно-сосудистыми заболеваниями обусловила широкое применение в клинической практике антикоагулянтной терапии. Длительное время основным антикоагулянтом, применяемым по этим показаниям, был препарат варфарин. При этом одними из наиболее распространенных осложнений были кровотечения, в т. ч. внутричерепные кровоизлияния. В последнее время все большее распространение получают новые оральные антикоагулянты (НОАК). Это определило необходимость сравнительной оценки их безопасности и эффективности с «классическим» антикоагулянтом варфарином, которая была проведена в ряде обширных клинических исследований этих лекарственных средств. Настоящий обзор посвящен анализу имеющихся данных о частоте внутричерепных кровоизлияний при применении антикоагулянтной терапии.

Об авторе

О. О. Шахматова
НИИ клинической кардиологии им. А.Л. Мясникова ФГБУ «Российский кардиологический научно-производственный комплекс» Минздрава России
Россия


Список литературы

1. Radberg JA, Olsson JE, Radberg CT. Prognostic parameters in spontaneous intracerebral hematomas with special reference to anticoagulant treatment. Stroke, 1991,22:571-6.

2. Hart RG, Tonarelli SB, Pearce LA. Avoiding central nervous system bleeding during antithrombotic therapy:

3. recent data and ideas. Stroke, 2005, 36(7): 1588-1593.

4. Flaherty ML, Kissela B, Woo D et al. The increasing incidence of anticoagulant-associated intracerebral hemorrhage. Neurology, 2007,68(2): 116-121.

5. Daniel M. Witt, Thomas Delatea, Elaine M. Hylekc et al. Effect of warfarin on intracranial hemorrhage incidence and fatal outcomes. Thrombosis Research, 2013, 132: 770-775.

6. Steiner T, Rosand J, Diringer M. Intracerebral hemorrhage associated with oral anticoagulant therapy: current practices and unresolved questions. Stroke, 2006, 37(1): 256-262.

7. Бойцов С.А., Якушин С.С., Марцевич С.Ю. и соавт. Амбулаторно-поликлинический регистр кардиова-скулярных заболеваний в Рязанской области (РЕК-ВАЗА): основные задачи, опыт создания и первые результаты. РФК, 2013,9(1): 4-14.

8. Якушин С.С. Оптимальная медикаментозная тера-

9. пия в клинике внутренних болезней: от клинических рекомендаций к реальной практике. Доклад на XIII Межрегиональной конференции РНМОТ. Режим доступа: http://www.rnmot.ru/public/ files/library/1/belgorod_2014_23.pdf.

10. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. NEnglJMed 2009, 361: 1139-51.

11. Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S et al. Apixaban in patients with atrial fibrillation. NEnglJMed 2011, 364: 806-17.

12. Patel MR, Mahaffey Щ Garg J, Pan G, Singer DE, Hacke W et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011, 365:883-91.

13. Giugliano RP, Ruff CT, Braunwald E et al. Edoxaban versus Warfarin in Patients with Atrial Fibrillation. N EnglJMed 2013, 369: 2093-2104.

14. Ruff CT, Giugliano RP, Braunwald E et al. Comparison of the effi cacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014, 383: 955-962.

15. Sorensen R, Gislason G, Torp-Pedersen C et al. Dabigatran use in Danish atrial fibrillation patients in 2011: a nationwide study. BMJOpen 2013, 3: e002758. doi: 10.1136/bmjopen-2013-002758.

16. Larsen TB, Rasmussen LH, Skjњth F et al. Efficacy and safety of dabigatran etexilate and warfarin in «real-world» patients with atrial fibrillation: a prospective nationwide cohort study. JAm Coll Cardiol 2013,61: 2264-2273.

17. Kirley K, Qato DM, Kornfield R, et al. National trends in oral anticoagulant use in the United States, 2007 to 2011. Circ Cardiovasc Qual Outcomes 2012, 5: 615-21.

18. Southworth MR, Reichman ME, linger ЕЕ Dabigatran and postmarketing reports of bleeding. N EnglJ Med 2013,368:1272-1274.

19. Atrial Fibrillation Investigators: Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibril-

20. lation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994, 154 (13): 1449-1457.

21. Hankey GJ. Intracranial Hemorrhage and Novel Anticoagulants for Atrial Fibrillation: What Have We Learned? Curr Cardiol Rep 2014, 16:480.

22. Hart RG, Diener HC, Yang S, et al. Intracranial hemorrhage in atrial fibrillation patients during anticoagula-tion with warfarin or dabigatran: the RE-LY trial. Stroke. 2012,43: 1511-7.

23. Minmin Ma, Atte Meretoja, Leonid Churilov et al. Warfarin-associated intracerebral hemorrhage: Volume, anticoagulation intensity and location. Journal of the Neurological Sciences 2013, 332: 75—79.

24. Hankey GJ, Stevens SR, Piccini JP, et al. Predictors of intracranial hemorrhage among anticoagulated patients with atrial fibrillation: insights from the rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF). Stroke. 2012,43: A152.

25. Domingues-Montanari S, Hernandez-Guillamon M, Fernandez-Cadenas I et al. ACE variants and risk of intracerebral hemorrhage recurrence in amyloid angiopathy. Neurobiology of Aging 2011, 32: 551, 13-551:22.

26. Aguilar MI, Brott TG. Update in Intracerebral Hemorrhage. The Neurohospitalist, 2011, 1(3): 148-159.

27. El Ahmadieh TY, Aoun SG, Daou MR et al. New-generation oral anticoagulants for the prevention of stroke: Implications for neurosurgery. Journal of Clinical Neuroscience 2013, 20: 1350-1356.

28. Mackman N. The role of tissue factor and factor VIIa in hemostasis. Anesth Analg 2009, 108: 1447-52.

29. Diener HC, Connolly SJ, Ezekowitz MD, et al. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. LancetNeurol 2010, 9: 1157-63.

30. Lee KR, Colon GP, Betz AL et al. Edema from intracerebral hemorrhage: the role of thrombin.J Neurosurg 1996, 84(1): 91-96.

31. Xi G, Reiser G, Keep RF. The role of thrombin and thrombin receptors in ischemic, hemorrhagic and traumatic brain injury: deleterious or protective?J Neurochem 2003, 84(1): 3-9.

32. lvaro Cervera, Sergio Amaro, Angel Chamorro. Oral anticoagulant-associated intracerebral hemorrhage.J Neurol 2012, 259:212-224.

33. Fang MC, Go AS, Chang Y, Hylek EM, Henault LE, Jensvold NG, et al. Death and disability from warfarin-associated intracranial and extracranial hemor-rhages.AmJMed 2007, 120: 700-5.

34. Morgenstern LB, Hemphill JC 3rd, Anderson C et al. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2010,41: 2108-29.

35. Диагностика и лечение фибрилляции предсердий. Рекомендации РКО, ВНОА и АССХ. Российский кардиологический журнал, 2014,4, 3.

36. Lip GH, Andreotti F, Fauchier L et al. Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis. Europace 2011, 13 (5): 723-746.

37. Levi M, Eerenberg E, Kamphuisen PW. Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents. J Thromb Haemost 2011,9: 1705-12.

38. Schiele F, van Ryn J, Canada K, et al. A specific antidote for dabigatran: functional and structural characterization. Blood 2013,121: 3554-62.

39. Glund S, Stangier J, Schmohl M, et al. A specific antidote for dabigatran: immediate, complete and sustained reversal of dabigatran induced anticoag-ulation in healthy male volunteers. Oral presentation number 17765 at 0930am on Monday November 18, 2013 at the American Heart Association Scientific Sessions (Room C140), Dallas, Texas, USA.

40. Lu G, DeGuzman FR, Hollenbach SJ, et al. Aspecific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. NatMed. 2013, 19:446-51.

41. Crowther MA, Kitt M, McClure M, et al. Randomized, double-blind, placebo-controlled single ascending dose pharmacokinetic and pharmacodynamic study of PRT064445, a universal antidote for factor Xa inhibitors (abstract). Arterioscler Thromb Vasc Biol 2013, 33: A10.

42. Crowther MA, Kitt M, Lorenz T, et al. A phase 2 randomized, doubleblind, placebo-controlled trial of PRT064445, a novel, universal antidote for direct and indirect factor Xa inhibitors (abstract).J Thromb Haemost 2013, 11: AS20.1.

43. Laulicht B, Bakhru S, Lee C, et al. Small molecule antidote for anticoagulants (abstract). Circulation 2012, 126: 10021.

44. Laulicht B, Bakhru S, Jiang X, et al. Antidote for new oral anticoagulants: mechanism of action and binding specificity of PER977 (abstract).J Thromb Haemost 2013, 11: AS47.1.

45. Stollberger C, Finsterer J. Reservations against new oral anticoagulants after stroke and cerebral bleeding. Journal of the Neurological Sciences 2013, 330: 16-17.

46. O'Donnell HC, Rosand J, Knudsen KA, et al. Apolipoprotein E genotype and the risk of recurrent lobar intracerebral hemorrhage. NEnglJMed 2000, 342(4): 240-245.

47. Eckman MH, Rosand J, Knudsen KA, et al. Can patients be anticoagulated after intracerebral hemorrhage? A decision analysis. Stroke, 2003, 34(7): 1710-1716.

48. Jauch EC, Saver JL, Adams HP Jr et al. Guidelines for the early management of patients with acute ischaemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke, 2013,44:870-947.

49. Hankey GJ. Unanswered questions and research priorities to optimise stroke prevention in atrial fibrillation with the new oral anticoagulants. Thromb Haemost, 2014, 111:808-816.


Для цитирования:


Шахматова О.О. ПРОБЛЕМА ВНУТРИЧЕРЕПНЫХ КРОВОИЗЛИЯНИЙ НА ФОНЕ ПРИЕМА «НОВЫХ» АНТИ КОАГУЛЯНТОВ. Атеротромбоз. 2014;(2):58-69. https://doi.org/10.21518/2307-1109-2014-2-58-69

For citation:


. . Atherothrombosis Journal. 2014;(2):58-69. (In Russ.) https://doi.org/10.21518/2307-1109-2014-2-58-69

Просмотров: 325


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2307-1109 (Print)
ISSN 2658-5952 (Online)